AstraZeneca's Oncology Business Delivers, Edging Toward CV/Metabolic As Top Contributor

The fast-growing oncology business represented 29% of AstraZeneca's second quarter sales, fueled by 44% revenue growth, outpacing sales of respiratory drugs and narrowing the gap with CV/metabolic.